Back to search

Virginia Commonwealth University

COST-EFFECTIVENESS ANALYSIS OF DIRECT-ACTING ANTIVIRAL STRATEGIES FOR HEPATITIS C POSITIVE DONOR TO NEGATIVE RECIPIENT KIDNEY TRANSPLANTATION

Abstract

dc:description.abstract

<p><strong>Background. </strong>Short-duration direct-acting antiviral (DAA) administration achieves sustained virologic response in hepatitis C virus (HCV)-positive donor to negative recipient (D+/R−) kidney transplants; however, the cost-effectiveness of the DAA strategies has not been comprehensively evaluated using contemporary real-world transmission data and the most recent drug pricing. We sought to determine the most cost-efficient DAA strategy using data from the Ultra-short <strong>D</strong>irect acting <strong>A</strong>nti-viral <strong>P</strong>rophylaxis to <strong>P</strong>r<strong>e</strong>vent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant <strong>R</strong>ecipients (DAPPeR) trial experience of 204 consecutive D+/R− kidney transplants and current drug acquisition costs, comparing it to other published strategies.</p> <p><strong>Methods. </strong>We developed a decision model to estimate the cost-effectiveness of several DAA strategies from the perspective of the health system. In this analysis, we compared 5 DAA strategies: (1) 7-day sofosbuvir/velpatasvir (SOF/VEL); (2) 8-day glecaprevir/pibrentasvir (G/P); (3) 4-week SOF/VEL; (4) 8-week G/P transmit-and-treat; and (5) 14-day G/P regimen. Drug costs were informed by wholesale acquisition cost (WAC) minus an assumed 30% institutional discount. Transition probabilities were derived from published clinical trials and the expanded DAPPeR study of 204 consecutive D+/R− kidney transplants. The outcome was defined as no HCV infection after each respective DAA administration.</p> <p><strong>Results. </strong>Strategy 2 (8-day G/P) was the least costly intervention (EEC: $2,640) with a 100% success rate, followed by Strategy 1 (7-day SOF/VEL; EEC: $5,273), Strategy 5 (14-day G/P; EEC: $5,544), Strategy 3 (4-week SOF/VEL; EEC: $5,600), and Strategy 4 (8-week G/P transmit-and-treat; EEC: $18,480). All short-duration treatment strategies were substantially less expensive than transmit-and-treat, with savings ranging from $12,880 to $15,840 per transplanted patient.</p> <p><strong>Conclusions. </strong>Short-duration DAA using 8-day G/P or 7-day SOF/VEL is the most cost-effective approach for HCV D+/R− kidney transplants. The choice between these strategies is sensitive to institution-specific drug pricing and real-world transmission rates, underscoring the need for individualized economic evaluations.</p>

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
Thesis
Discipline thesis:degree_discipline
Pharmaceutical Sciences

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Yakubu, Idris
  • https://orcid.org/0000-0002-7871-3479
Contributors dc:contributor
  • Vasco Pontinha

Subjects

dc:subject × 8

Rights

dc:rights
Statement dc:rights
  • © The Author

Identifiers

dc:identifier.*
Repository record dc:identifier
https://scholarscompass.vcu.edu/etd/8509

Chain of custody

source
Harvested from
Virginia Commonwealth University
Base URL
scholarscompass.vcu.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Yakubu, Idris; https://orcid.org/0000-0002-7871-3479. COST-EFFECTIVENESS ANALYSIS OF DIRECT-ACTING ANTIVIRAL STRATEGIES FOR HEPATITIS C POSITIVE DONOR TO NEGATIVE RECIPIENT KIDNEY TRANSPLANTATION. Thesis thesis, https://scholarscompass.vcu.edu/etd/8509